Strong uptrend for GSK — technicals support positive price forecast

Traders Union
All News
Financial News
GSK rises 0.74% to GBX 1,846.50

Highlights

GSK acquired 11.3 million to 11.7 million of its own shares since September 2025 under a non-discretionary buyback program with BNP Paribas SA.
Recent early December buybacks added 418,000 shares, increasing treasury shares to about 236.8 million, approximately 5.8% of total issued share capital.
The share repurchase aligns with GSK's capital management strategy, complementing a 3.4–3.5% dividend yield and a robust pipeline in oncology and vaccines.

Share buybacks and dividend yield as capital return priorities

GSK has continued executing its share buyback program, acquiring between 11.3 million and 11.7 million of its own shares since September 2025 through a non-discretionary agreement with BNP Paribas SA. Recent transactions in early December, including purchases of 218,000 and 200,000 shares, have increased treasury shares to about 236.8 million, around 5.8% of total issued share capital. The buybacks are part of GSK's capital structure management alongside a reported dividend yield of 3.4–3.5% and a robust pipeline in oncology and vaccines.

Overbought signals emerge as strong trend meets new resistance

The nearest dynamic support is the Ichimoku Kijun at GBX 1,756, while MA-50 (GBX 1,706.26) acts as further support, with resistance now shifting to round levels above the current price. Momentum indicators on the daily chart remain strong, with MACD showing a "Strong Buy" and ADX at a healthy 26.2, reflecting a robust trend. However, there is a notable overbought signal from Stoch RSI (100), CCI (195.69), and RSI (66.09), while BBP confirms buyers are currently dominating. The Awesome Oscillator is neutral and does not reinforce the immediate uptrend. Today's session shows a modest gap down at the open (GBX 1,827.13 vs. the previous close of GBX 1,833.00), but the price has rebounded, trading near the upper end of today’s range (GBX 1,827.00 — 1,853.00). Intraday volatility is moderate with a steady upward tone, though the overbought oscillators suggest momentum could stall or retrace in the near term.

Sideways bias likely as high probability of gains counters overbought risk

For the next five trading days, the expected price range is GBX 1,841.00 to GBX 1,950.00, in line with typical volatility. The probability of a further price rise is very high (more than 80%), while a pullback appears less likely. The baseline scenario is continued sideways movement as overbought signals unwind. A bullish case would see a break above GBX 1,850 — 1,900, targeting the forecast high, while a drop below GBX 1,841.00 could trigger a short-term correction toward dynamic support levels.

Viktoras Karapetjanc, analyst at Traders Union, notes that GSK demonstrates strong bullish momentum across all timeframes. The ongoing buyback program and stable dividends reflect underlying institutional confidence and balance sheet strength. He sees recent overbought signals as a cause for short-term caution, but the medium-term outlook is underpinned by solid fundamentals and positive sentiment. The probability of further gains remains high, though minor pullbacks are possible as the market digests recent upside. "As long as GSK holds above key support levels, I expect sustained upward movement driven by robust fundamentals and optimistic sentiment."

Previously it was reported that GSK traded decisively above all major moving averages, with strong momentum signaled by bullish MACD, ADX, and a constructive RSI, while persistent buying kept prices near recent highs. Support levels held firm at dynamic lines and the psychological threshold, with the probability of further gains considered elevated based on strong momentum signaled by bullish MACD and ongoing capital optimization efforts.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.